 |
|
24.05.2010 Cell Therapeutics, Inc. Announces
Institutional Investors Purchase $21.0 Million of Preferred Stock
and Warrants |
|
Cell Therapeutics,
Inc. ("CTI") (NASDAQ and MTA: CTIC)
today announced that it has entered into an agreement to
sell $21.0 million of shares of its Series 5 Preferred Stock in a
registered offering to three institutional investors (collectively,
the "Initial Purchasers"). Each share of Series 5 Preferred Stock is
convertible at the option of the holder, at any time during its
existence, into 2,500 shares of common stock at a conversion price
of $0.40 per share of common stock, for a total of 52,500,000 shares
of common stock.
 |
 |
|
|
|
|
|
|
|
24.05.2010 OPAXIO Phase II Study in Patients
with Advanced Esophageal Cancer Results to be Presented at the
American Society of Clinical Oncology 2010 Annual Meeting |
|
Cell Therapeutics, Inc.
("CTI") (NASDAQ and MTA: CTIC) announced
today that phase II study results from Brown University will be
presented by Kimberly Perez, M.D., Hematology/Oncology Fellow with
the Warren Alpert School of Medicine of Brown University, at the
American Society of Clinical Oncology Annual Meeting in Chicago,
Illinois on Sunday, June 6, 2010. The abstract, #4085, title is "Neoadjuvant
Paclitaxel Poliglumex (PPX), Cisplatin and Radiation (RT) for
Esophageal Cancer." The trial studied OPAXIO in patients with cancer
of the lower esophagus giving OPAXIO(TM) (paclitaxel poliglumex), a
biologically enhanced paclitaxel, administered in combination with
standard cisplatin and concurrent radiation. CTI plans to meet with
the FDA in the second half of 2010 to explore a potential phase III
registration study based on these results.
|
|
|
|
|
|
|
|
|
20.05.2010 Roche and Genentech to Present New Data on Different
Approaches to Treating Cancer at ASCO |
|
Genentech, Inc., a wholly owned
member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
today announced that it will present new data for its
targeted cancer medicines and the way they may be used
in several different cancer types at the 46th Annual
Meeting of the American Society of Clinical Oncology
(ASCO). Approximately 400 abstracts featuring Genentech
and Roche's cancer medicines and investigational agents
across 30 cancer types will be presented during the
meeting that is taking place June 4 to 8, 2010 in
Chicago.
|
 |
|
|
|
|
|
|
|
20.05.2010 Phase III Study
Showed First-Line Maintenance Use of Rituxan®
Improved the Likelihood of People with Follicular
Lymphoma Living without Their Disease Worsening |
|
Genentech, Inc., a
wholly owned member of the Roche Group
(SIX: RO, ROG; OTCQX: RHHBY), and Biogen
Idec (Nasdaq: BIIB) today announced data
from the Phase III PRIMA study. The data
showed that continuing Rituxan® (rituximab)
for two years in patients who responded
to initial treatment with Rituxan plus
chemotherapy, doubled the likelihood of
them living without their disease
worsening (progression-free survival or
PFS) compared to those who stopped
treatment (based on a hazard ratio of
0.50, 95% CI, 0.39; 0.64; p=<0.0001).
The study enrolled patients with
previously untreated advanced follicular
lymphoma. After two-years of follow-up,
82 percent of patients who received
Rituxan maintenance were in remission
compared to 66 percent of patients who
did not. No new safety signals were
observed in this study and the safety
profile was consistent with previous
experience with Rituxan.
|
|
|
|
|
 |
|
|
20.05.2010 Critical Outcome Technologies Inc. Discovers Novel
Scaffolds For Inhibiting HIV Integrase |
|
Critical Outcome Technologies Inc.
(COTI) (TSX Venture: COT) today announced positive
results from the first phase of its HIV integrase
inhibitor discovery program. These results provide
novel intellectual property to the Company and further
validation of the CHEMSAS® drug discovery technology.
|
 |
|
|
|
|
|
|
|
19.05.2010 Ambry Genetics Introduces AmbryScreen™, A Genetic Test
Screening For Some of The Most Common And Severe Genetic Disorders
Affecting Newborns |
|
Ambry
Genetics
announced today at the
American College of Obstetricians and Gynecologists
annual clinical meeting the launch of AmbryScreen™, a
genetic screening test used to identify carriers of some
of the most severe and common childhood diseases
affecting pan-ethnic populations. Designed by a team of
geneticists and genetic counselors with decades of
clinical and laboratory experience, the panel is a
responsible and ethical means of identifying individuals
at high risks to have a child with severe genetic
conditions. As with all clinical assays performed by
Ambry Genetics, the test must be ordered by a physician.
It is not available direct to consumer.
|
 |
|
|
|
|
|
|
|
18.05.2010 Pixantrone Associated With Up to
4-Fold Reduction in Severe (Grade 3-4) Cardiac Toxicity When
Compared to Doxorubicin in CHOP-R Regimen |
|
Cell Therapeutics, Inc.
("CTI") (Nasdaq and MTA: CTIC)
(the "Company") reported today
preliminary cardiac safety results from a North American randomized
phase II trial which substituted pixantrone for doxorubicin in the
standard CHOP-R regimen. Called PIX203, the randomized trial
compared CPOP-R directly to CHOP-R in the 1st line treatment of high
risk patients with diffuse large B cell non-Hodgkin's lymphoma
(DLBCL, NHL).
|
|
|
|
|
|
|
|
|
18.05.2010 Molecular Detection Inc.
and Launch Diagnostics ltd. Announce Distribution Agreement and
Launch of Detect-Ready™ MRSA Assay in UK and Ireland |
|
|
Molecular
Detection Inc.
(MDI), a company
developing Detect-Ready™ assays
designed to increase the speed and accuracy of
infectious disease diagnosis, and Launch
Diagnostics Ltd. today announced an exclusive
distribution agreement for MDI’s Detect-Ready
MRSA assay in the UK, France and Republic of
Ireland. They also announced the
commercial launch of the Detect-Ready MRSA
assay, which offers healthcare providers a high
performance MRSA screening test with an
unmatched combination of accuracy, speed,
flexibility and cost-effectiveness, in the UK
and the Republic of Ireland . Launch
Diagnostics is a leading independent distributor
of quality medical products including
clinical diagnostics,
instrumentation and consumables.
|
 |
|
|
|
|
|
|
|
16.05.2010 Agilent Technologies
Completes Acquisition of Varian, Inc., Marking Historic Milestone
for Two Silicon Valley Pioneers
|
|
Agilent Technologies Inc.
(NYSE: A) today
announced that its acquisition of scientific-equipment maker Varian,
Inc. is now final, positioning Agilent as a leading provider of
analytical instrumentation to the applied and life sciences markets.
Agilent paid approximately $1.5 billion in cash for Varian in a deal
that brings together two Silicon Valley pioneers.
|
 |
|
|
|
|
|
|
|
14.05.2010 Amgen Submits Denosumab Biologics
License Application to FDA for the Reduction of Skeletal Related
Events in Cancer Patients |
|
Amgen
(Nasdaq:
AMGN), today announced the submission of a Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA) for
denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission
summarizes clinical experience from nearly 6,900 patients across 18
clinical studies, including approximately 5,700 patients with
advanced cancer in the three, pivotal, Phase 3, head-to-head trials
versus Zometa(R) (zoledronic acid).
|
 |
|
|
|
|
|
|
|
13.05.2010 Cell Therapeutics Announces
Agreement for Phase II Study of Pixantrone in Metastatic Breast
Cancer |
|
Cell Therapeutics, Inc.
("CTI") (Nasdaq and MTA: CTIC)
(the "Company")
today announced an agreement with the North Central Cancer Treatment
Group (NCCTG) to conduct a phase II study of pixantrone in patients
with HER2-negative metastatic breast cancer who have tumor
progression after at least two, but not more than three, prior
chemotherapy regimens. The trial will be conducted through the
NCCTG, a national network of cancer specialists at community
clinics, hospitals, and medical centers in the United States and
Canada. The research base for NCCTG is located at Mayo Clinic in
Rochester, MN.
|
|
|
|
|
|
|
|
|
12.05.2010 Amgen Announces Voting Results of
Annual Meeting of Stockholders |
|
Amgen
(Nasdaq: AMGN), today announced results of voting at the company's
Annual Meeting of Stockholders, held at the Four Seasons Hotel
Westlake Village in Westlake Village, Calif. Approximately 85
percent of outstanding shares were represented at the meeting.
|
|
|
|
|
|
|
|
|
04.05.2010 Vetter And Sentry
Biopharma Services Establish Preferred Partnership Agreement |
|
Vetter,
a leading
provider of aseptic pre-filled drug-delivery systems, and Sentry
BioPharma Services, a provider of supply chain management and
clinical packaging services, today announced that they have signed a
preferred partnership agreement. Vetter will fill early-stage,
high-value biopharmaceuticals at its Chicago facility; Sentry will
label, package and ship the clinical supplies from its site in
Indianapolis, Indiana. The collaboration will help streamline the
path of study drugs from filling lab to clinic while safeguarding
product integrity.
|
 |
|
|
|
|
|
|
|
03.05.2010 ACADIA Pharmaceuticals to
Announce First Quarter 2010 Financial Results on May 10, 2010 |
|
ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD),
a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical
development of novel treatments for central
nervous system disorders, today announced that
it will report its unaudited financial results
for the first quarter ended March 31, 2010 on
Monday, May 10, 2010, after the U.S. financial
markets close. ACADIA's management will host a
conference call and webcast on Monday, May 10,
2010, at 5:00 p.m. Eastern Time to discuss
ACADIA's financial results and development
programs.
|
 |
|
|
|
All rights reserved